Similar articles

• Preclinical studies of T-cell-mediated immune responses against autologous tumor cells in patients with acute leukemia.

  Notter M, Ludwig WD, Thiel E. Notter M, et al. Recent Results Cancer Res. 1993;131:215-22. doi: 10.1007/978-3-642-84895-7_19. Recent Results Cancer Res. 1993. PMID: 8210641 Review. No abstract available.
• Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

  Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Nagorsen D, et al. Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Leuk Lymphoma. 2009. PMID: 19455460 Review.
• Immunological aspects of human leukaemia.

  Viza D. Viza D. Ser Haematol. 1972;5(5):87-108. Ser Haematol. 1972. PMID: 4133766 Review. No abstract available.
• [Redirected T cell-based antileukemia adoptive immunotherapy using tumor antigen-specific TCR gene transfer].

  Fujiwara H. Fujiwara H. Rinsho Ketsueki. 2014 Jun;55(6):657-69. Rinsho Ketsueki. 2014. PMID: 24975335 Japanese. No abstract available.
• Continuous culture of T cells cytotoxic for autologous human leukaemia cells.

  Zarling JM, Bach FH. Zarling JM, et al. Nature. 1979 Aug 23;280(5724):685-8. doi: 10.1038/280685a0. Nature. 1979. PMID: 224318 No abstract available.